Navigation Links
Sunesis in Medical News

Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs

NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory an...

Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors

...ANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ent. "We are pleased to have Helen join the sunesis Board of Directors," said Daniel Swisher, Sunesis'... track record and commercial insights will benefit sunesis significantly." Ms. Kim is currently a Dire...

Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

...ANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... term of this collaboration ended in June of 2008. sunesis retains an option to participate in the co-develop...tor resulting from this collaboration. About sunesis Pharmaceuticals ...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO

...RANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... Additionally at the ASCO 2009 Annual Meeting, sunesis will be presenting clinical data on SNS-314, a nov...ll of these presentations will be available on the sunesis website at www.sunesis.com on the same day eac...

Sunesis Reports Financial Results for the First Quarter 2009

...FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis announced the execution of a securities purchase a...acement, among other conditions. In April, sunesis presented data on voreloxin at the American Associ...

Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing

...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ate placement, and which is subject to approval by sunesis Pharmaceuticals' stockholders and the satisfaction...chievement of a specific milestone with respect to sunesis Pharmaceuticals' voreloxin product candidate and...

Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill

...such as Cephalon, Inc. [CEPH], Genentech, Inc. [DNA], Infinity Pharmaceuticals, Inc. [INFI], Memory Pharmaceuticals Corp., Pharmos Corporation [PARS], sunesis Pharmaceuticals, Inc. [SNSS] and Vertex Pharmaceuticals Incorporated [VRTX]. At this point, we believe that the Company's only legitimate option ...

Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research

...ncer where topoisomerase II poisons are active." sunesis researchers conducted in vitro and cell-based stud...ancer. In a third set of studies reported today, sunesis researchers profiled the potential relationship be...sed previously in the treatment of cancer. About sunesis Pharmaceuticals ...
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

More>>

Sunesis in Biological Technology

Sunesis Receives Approval for Listing on The NASDAQ Capital Market

...ANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...ve at the opening of the market on August 3, 2009. sunesis will continue to trade under the symbol "SNSS." ...adhere to NASDAQ's corporate governance standards. sunesis requested the transfer of its listing based upon t...

Sunesis Reports Financial Results for the Second Quarter 2009

...ANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis completed a $10.0 million initial closing of a tra...$8.8 million. The remaining units may be issued by sunesis upon the satisfaction of a clinical milestone and ...

Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference

...ANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...cast of this presentation will be available on the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About...

Sunesis Pharmaceuticals Receives NASDAQ Notification

...NCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) reported t... by the Panel following the hearing. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo...s totaled $10.6 million, with no outstanding debt. sunesis Pharmaceuticals separately announced today the exe...d at all three dose levels. In March 2009, sunesis sold to SARcode Corporation all of the company's i...

Sunesis to Present at the 11th Annual BIO CEO & Investor Conference

...f the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

...ANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today prov...eloxin study in AML by the end of this year." sunesis is providing an update on the progress of its vore...Phase 2 and 1b/2 Studies of Voreloxin in AML sunesis is evaluating single agent voreloxin in an ongoing...

Sunesis to Present at Upcoming Conferences

...UTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...st of these presentations will be available on the sunesis website at http://ir.sunesis.com . A replay of t...ts" page in the Investors and Media section of the sunesis website for two weeks. About...

Sunesis to Present at Upcoming Conferences

...w and Lazard Capital presentations by visiting the sunesis website at http://ir.sunesis.com . A replay of th...tion of the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...

Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...
Other Tags
(Date:10/2/2014)... Brooklyn, PA (PRWEB) October 02, 2014 ... through social engineering announced today it will host a ... The webinar will reveal the final outcome of ... at DEF CON 22 in Las Vegas and explore ... evolving social engineering attacks. To register for the ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... literally -- may face an increased risk of dying in the ... over 3,000 older Americans, researchers found those who were unable to ... three times as likely to die in the next five years, ... anosmia -- the inability to distinguish odors -- was a bigger ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
Other Contents